Chemokine presents positive preclinical data for cancer drug

The study has used a mouse model that spontaneously forms breast cancer. These tumors develop and spread to the lungs at known developmental time points. Such models are prized in cancer research because the tumor is not a foreign tissue that is implanted in the animal.

The results of the study showed that CTCE-9908 treatment by itself has an effect on reducing the tumor size in the breast and consistently reduced the number of metastases in the lungs by about one half. Also, adding CTCE-9908 to chemotherapy further inhibited the primary tumor compared to chemotherapy alone and supplementing CTCE-9908 to an anti-angiogenic drug similar to the cancer drug Avastin, further increased the efficacy of the therapy.

Walter Korz, president and CEO of Chemokine, said: “We are excited by the potential of CTCE-9908 to enhance the efficacy of established chemotherapy as well as that of the emerging new generation of targeted cancer therapies on both the primary tumor and the metastatic process.”